1. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma. (14th February 2020) Authors: Lee, Hun J.; Schmelz, Jacob L.; Cramer, Fred; Romaguera, Jorge E.; Badillo, Maria; Wang, Michael Journal: British journal of haematology Issue: Volume 188:Number 6(2020) Page Start: e94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma. (12th March 2018) Authors: Lee, Hun J.; Badillo, Maria; Romaguera, Jorge; Wang, Michael Journal: British journal of haematology Issue: Volume 184:Number 3(2019) Page Start: 460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. Issue 7 (6th May 2021) Authors: Lee, Hans C.; Feng, Lei; Oriabure, Onyeka; Graham, Vivian; Chen, Wendy; Badillo, Maria; Lu, Rebecca; Lee, Hun J.; Jain, Preetesh; Manasanch, Elisabet E.; Orlowski, Robert Z.; Wang, Michael L. Journal: American journal of hematology Issue: Volume 96:Issue 7(2021) Page Start: E243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients. Issue 6 (17th April 2020) Authors: Zhao, Shuangtao; Kanagal‐Shamanna, Rashmi; Navsaria, Lucy; Ok, Chi Young; Zhang, Shaojun; Nomie, Krystle; Han, Guangchun; Hao, Dapeng; Hill, Holly A.; Jiang, Changying; Yao, Yixin; Nastoupil, Loretta; Westin, Jason; Fayad, Luis; Nair, Ranjit; Steiner, Raphel; Ahmed, Sairah; Samaniego, Felipe; Iye... Journal: American journal of hematology Issue: Volume 95:Issue 6(2020:Jun.) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). (22nd May 2018) Authors: Jain, Preetesh; Romaguera, Jorge; Srour, Samer A.; Lee, Hun J.; Hagemeister, Frederick; Westin, Jason; Fayad, Luis; Samaniego, Felipe; Badillo, Maria; Zhang, Liang; Nastoupil, Lorreta; Kanagal‐Shamanna, Rashmi; Fowler, Nathan; Wang, Michael L. Journal: British journal of haematology Issue: Volume 182:Number 3(2018) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Issue 1 (January 2016) Authors: Wang, Michael L; Lee, Hun; Chuang, Hubert; Wagner-Bartak, Nicolaus; Hagemeister, Frederick; Westin, Jason; Fayad, Luis; Samaniego, Felipe; Turturro, Francesco; Oki, Yasuhiro; Chen, Wendy; Badillo, Maria; Nomie, Krystle; Rosa, Maria DeLa; Zhao, Donglu; Lam, Laura; Addison, Alicia; Zhang, Hui; Youn... Journal: Lancet oncology Issue: Volume 17:Issue 1(2016:Feb.) Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Issue 2 (10th January 2022) Authors: Jain, Preetesh; Zhao, Shuangtao; Lee, Hun Ju; Hill, Holly A.; Ok, Chi Young; Kanagal-Shamanna, Rashmi; Hagemeister, Fredrick B.; Fowler, Nathan; Fayad, Luis; Yao, Yixin; Liu, Yang; Moghrabi, Omar B.; Navsaria, Lucy; Feng, Lei; Nogueras Gonzalez, Graciela M.; Xu, Guofan; Thirumurthi, Selvi; Santos... Journal: Journal of clinical oncology Issue: Volume 40:Issue 2(2022) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Issue 3 (March 2022) Authors: Wang, Michael L; Jain, Preetesh; Zhao, Shuangtao; Lee, Hun Ju; Nastoupil, Loretta; Fayad, Luis; Ok, Chi Young; Kanagal-Shamanna, Rashmi; Hill, Holly A; Yao, Yixin; Hagemeister, Fredrick B; Westin, Jason R; Fowler, Nathan; Samaniego, Felipe; Steiner, Raphael; Nair, Ranjit; Iyer, Swaminathan P; Nav... Journal: Lancet oncology Issue: Volume 23:Issue 3(2022) Page Start: 406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment. (8th May 2018) Authors: Romaguera, Jorge E.; Lee, Hun J.; Tarapore, Rohinton; Prabhu, Varun; Allen, Joshua; Schalop, Lee; Zloza, Andrew; Ok, Chi Y.; Sadimin, Evita T.; Schenkel, Jason; Badillo, Maria; Wang, Michael Journal: British journal of haematology Issue: Volume 185:Number 1(2019) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. (2nd September 2018) Authors: Jain, Preetesh; Kanagal‐Shamanna, Rashmi; Zhang, Shaojun; Ahmed, Makhdum; Ghorab, Ahmad; Zhang, Liang; Ok, Chi Young; Li, Shaoying; Hagemeister, Frederick; Zeng, Dongfeng; Gong, Tiejun; Chen, Wendy; Badillo, Maria; Nomie, Krystle; Fayad, Luis; Medeiros, Leonard J.; Neelapu, Sattva; Fowler, Nathan... Journal: British journal of haematology Issue: Volume 183:Number 4(2018) Page Start: 578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗